Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives $24.00 Average PT from Brokerages

Artelo Biosciences, Inc. (NASDAQ:ARTL) has earned an average rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.00.

Several equities analysts have recently issued reports on ARTL shares. Maxim Group reaffirmed a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th. D Boral Capital cut shares of Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a report on Monday, December 1st. Finally, D. Boral Capital reissued a “hold” rating on shares of Artelo Biosciences in a research report on Monday, September 8th.

Artelo Biosciences Stock Up 0.5%

Shares of ARTL opened at $1.95 on Friday. The stock has a market cap of $3.94 million, a P/E ratio of -0.09 and a beta of 1.07. The business’s 50 day moving average price is $2.68 and its 200-day moving average price is $6.89. Artelo Biosciences has a 52 week low of $1.52 and a 52 week high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($3.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($3.15). On average, equities analysts anticipate that Artelo Biosciences will post -2.62 EPS for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.